Pharma Stock Flies on Q3 Report, Analyst Praise

No fewer than nine analysts raised their price targets

Deputy Editor
Nov 3, 2020 at 10:25 AM
facebook twitter linkedin


The shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) are up 5.9% at $156 at last check, after a third-quarter earnings and revenue beat. To follow, no fewer than nine analysts raised their price targets, with the highest coming from SVB Leerink to $202 from $194. 

On the charts, today's gap higher has JAZZ closing in on its Oct.12 annual high of $156.26. Breaking above recent pressure at the 10-day moving average, the equity has just surpassed its year-to-date breakeven, a 1.4% discount to yesterday's close. 

The brokerage bunch is overwhelmingly bullish, with 13 of the 14 analysts in coverage at a "buy" or better rating, and the outlier at a tepid "hold." Meanwhile, the 12-month consensus price target of $180.06 is a 19.9% premium to current levels. 

Also worth noting, though short interest has started to fall off, the 4.17 million shares sold short still account for 7.8% of the stock's available float, and would take nearly six days to cover at JAZZ's average pace of trading. As these bearish bets continue to unwind, it could provide a tailwind for the security. 

 

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners